1364TiP Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy

Autor:	J. De Castro Carpeno, A. Blasco Cordellat, Byoung Cheol Cho, A-L. Bauchet, A. Tomova, S. Bensfia, Jaquelline Germano de Oliveira, C. Aguado de la Rosa, T.M. Kim, L. Vilà, G. Dy, Dolores Isla, C. Soufflet
Rok vydání:	2021
Předmět:	Antitumor activity Chemotherapy business.industry medicine.medical_treatment Hematology Immunotherapy medicine.disease Ramucirumab Oncology Pharmacokinetics Non squamous Cancer research medicine Non small cell Lung cancer business
Zdroj:	Annals of Oncology. 32:S1034-S1035
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::50d46e86bd869e5e4992c6cc7efd02ed https://doi.org/10.1016/j.annonc.2021.08.1965 Zobrazit plný text záznamu